Lucira Health Announces Fourth Quarter and Full Year 2021 Results and Reaffirms 2022 Financial Outlook
03/10/2022 - 04:01 PM
EMERYVILLE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial results for the fourth quarter and full year ended December 31, 2021.
Recent Highlights
Achieved net revenue of $61.1 million for the fourth quarter of 2021, representing approximately 300% sequential growth over the preceding quarter Recorded full year revenue of $93.1 million for 2021, the Company’s first full year of commercialization Increased manufacturing output through the Dominican Republic-based plant resulted in positive gross profit and margin for both the fourth quarter and the full year 2021 Secured contract with Canadian healthcare company, Switch Health, to provide more than 2 million at-home COVID-19 test kits in 2022 “Lucira’s strong fourth quarter is indicative of the inflection point the Company is experiencing in its growth,” said Erik Engelson, President and Chief Executive Officer of Lucira Health. “The strong financial performance was a result of a rise in manufacturing output against consistently high demand in the quarter. We offer consumers an easy-to-use, rapid, PCR-quality test that’s untethered from instruments or readers. It’s a revolutionary way to accurately and conveniently test for infectious disease, and we look forward to capitalizing on the market’s continued acceptance of decentralized testing in the future.”
Fourth Quarter 2021 Financial Results
The fourth quarter of 2021 represented Lucira's first full fourth quarter of commercial activity.
Net Revenue was $61.1 million for the fourth quarter of 2021, close to doubling the combined three prior quarters in 2021 of $31.9 million . Net revenue growth was driven primarily by increased manufacturing output as demand continued to be strong in all four of our sales channels.
GAAP Gross Profit was approximately $12.6 million for the fourth quarter of 2021 or 21% of revenue. Non-GAAP gross profit and non-GAAP gross margin were $19.1 million and 31% , respectively. Increases in both gross profit and gross margin from the third quarter of 2021 were primarily due to efficiencies resulting from increased manufacturing output.
GAAP Operating Expenses were $20.6 million in the fourth quarter of 2021, compared to $10.9 million in the same period in 2020. Non-GAAP operating expenses were $19.0 million in the fourth quarter of 2021, compared to $11.6 million in the same period of 2020. The increase is primarily related to increased headcount and third-party services to facilitate commercial activities, validation of manufacturing activities, new product development, clinical studies, and public company compliance.
GAAP Net Loss was $7.8 million in the fourth quarter of 2021, compared to $17.2 million in the same period in 2020. Non-GAAP net income was $0.3 million for the fourth quarter of 2021, compared to a non-GAAP net loss of $13.1 million for the same period in 2020.
Cash Balance as of December 31, 2021 was $106.0 million .
First Quarter and Full Year 2022 Financial Guidance
The Company anticipates first quarter revenue between $80.0 and $85.0 million and 2022 full year revenue in excess of $450.0 million , in keeping with an announcement the Company previously made on January 10, 2022.
Conference Call and Webcast Details
The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Thursday, March 10, 2022, at 4:30 PM ET.
To participate in the call, please dial (833) 562-0151 (US/Canada) or (661) 567-1232 (International) and provide conference ID 9897752. A live and archived webcast of the event can be accessed through the following link ir.lucirahealth.com .
About Lucira Health
Lucira is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira's testing platform produces lab quality molecular testing in a single-use, consumer-friendly, palm-size test kit powered by two AA batteries. Lucira designed its test kits to provide accurate, reliable, and on-the-spot molecular test results anywhere and at any time. The Lucira™ Check-It COVID-19 Test Kit (OTC) and Lucira™ COVID-19 All-In-One Test Kit (Rx) are designed to provide a clinically relevant COVID-19 result within 30 minutes from sample collection. For more information, visit www.lucirahealth.com .
Non-GAAP Financial Measures
Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies, which could reduce the usefulness of the Company's non-GAAP financial measures as tools for comparison. Investors are cautioned that there are a number of limitations associated with the use of non-GAAP financial measures as analytical tools. The Company has provided at the end of this press release, following the accompanying financial data, reconciliations of its non-GAAP measures to their most directly comparable GAAP measures. Investors are encouraged to review these reconciliations, and not to rely on any single financial measure to evaluate the Company's business. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. Non-GAAP financial measures in this earnings release exclude the following:
Stock-based compensation expense. The Company has excluded the effect of stock-based compensation expenses in calculating the Company's non-GAAP gross profit (loss), gross (negative) margin, operating expenses and net loss measures. Although stock-based compensation is a key incentive offered to employees, consultants and board members the Company continues to evaluate its business performance excluding stock-based compensation expenses. The Company records stock-based compensation expense related to grants of time-based options and restricted stock units. Depending upon the size, timing and terms of the grants, as well as the probability of achievement of performance-based awards, this expense may vary significantly but will recur in future periods. The Company believes that excluding stock-based compensation expense better allows for comparisons from period to period.
Depreciation and amortization. The Company has excluded the effect of depreciation and amortization expense in calculating its non-GAAP gross profit (loss), gross (negative) margin, operating expenses and net loss measures. Depreciation and amortization are non-cash charges to current operations.
Non-cash interest and other expense. The Company has excluded the effect of non-cash interest and remeasurement of derivative liabilities and convertible notes in calculating its non-GAAP net loss measure.
Preapproval inventories. The Company has included the effect of preapproval inventories. Preapproval inventories were previously recorded as research and development expense during the third quarter of 2020 and subsequently sold at zero cost of product and internally consumed in research and development and sales and marketing from the fourth quarter of 2020 through the third quarter of 2021.
Long-lived asset impairment charge. The Company has excluded the impact of an impairment charge resulting from an asset with reduced fair value in calculating its non-GAAP gross profit (loss), gross (negative) margin and net loss measures.
Obsolete inventory. The Company has excluded the impact of certain obsolete inventory charges in calculating its non-GAAP gross profit (loss) gross (negative) margin and net loss measures.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "can," "aim," "will," "may," "anticipates," "expects," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Lucira's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including our ability to increase production, streamline operations and increase product availability; the success of our test platform with COVID-19 including its variants, the extent and duration of the COVID-19 pandemic and our expectations regarding customer and user demand for our COVID-19 test kit; our ability to obtain and maintain regulatory approval for our test kits, including our existing Emergency Use Authorization for our COVID-19 test kit and LUCI Pass; the performance of, and our reliance on, third parties in connection with the commercialization of our test kits, including Jabil Inc. Switch Health and our single-source suppliers; our ability to successfully continue to expand internationally; any impact on our ability to market our products; demand for our products due to deferral of procedures using our products or disruption in our supply chain; our ability to achieve or sustain profitability; our ability to gain market acceptance for our products and to accurately forecast and meet customer demand; our ability to compete successfully; our ability to enhance and expand our product offerings, broaden commercial activities and take advantage of growth opportunities; our ability to accurately predict continued expansion; our ability to accurately forecast revenue; our ability to bolster capital reserves and reinforce our financial health; development and manufacturing problems; capacity constraints or delays in production of our products; maintenance of coverage and adequate reimbursement for procedures using our products; and product defects or failures. These and other risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and Lucira assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
LUCIRA HEALTH, INC. CONDENSED BALANCE SHEETS (Unaudited) (In thousands, except share and per share data) December 31, 2021 2020 Assets Current assets: Cash $ 105,982 $ 58,212 Accounts receivable, net 27,245 293 Inventory 50,776 4,865 Other Receivable 8,188 798 Prepaid expenses 10,274 3,496 Other current assets 3,817 229 Restricted cash equivalents — 2,338 Total current assets 206,282 70,231 Property and equipment, net 30,974 19,408 Operating lease right-of-use assets 2,714 748 Other assets 384 2,316 Total assets $ 240,354 $ 92,703 Liabilities, Redeemable Convertible Preferred Stock, and Stockholders’ Equity (Deficit) Current liabilities: Accounts payable $ 19,371 $ 3,981 Accrued liabilities 29,162 4,445 Operating lease liabilities, current 1,609 431 Customer deposits 189 — Total current liabilities 50,331 8,857 Convertible notes payable — 24,694 Operating lease liabilities, net of current portion 1,220 380 Total liabilities 51,551 33,931 Commitments and contingencies Redeemable convertible preferred stock $0.00 1 par value; 0 and 103,355,827$0 as of December 31, 2021 — 121,080 Stockholders’ equity: Preferred stock $0.00 1 par value; 10,000,000 and 0 shares authorized as — — Common stock, $0.00 1 par value; 200,000,000 and 150,000,000 shares authorized as of 40 3 Additional paid-in capital 317,304 1,403 Accumulated deficit (128,541 ) (63,714 ) Total stockholders’ equity (deficit) 188,803 (62,308 ) Total liabilities, redeemable convertible preferred stock, and stockholders’ equity $ 240,354 $ 92,703
LUCIRA HEALTH, INC. CONDENSED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except share and per share data) Three Months Ended December 31, Twelve Months Ended December 31, 2021 2020 2021 2020 Net sales $ 61,124 $ 269 $ 93,055 $ 269 Cost of products sold 48,682 1,941 81,392 1,941 Impairment of long-lived assets (183 ) — 1,439 — Gross profit (loss) 12,625 (1,672 ) 10,224 (1,672 ) Operating expenses: Research and development 9,099 8,512 39,840 24,620 Selling, general and administrative 11,550 2,412 35,538 5,633 Total operating expenses 20,649 10,924 75,378 30,253 Loss from operations (8,024 ) (12,596 ) (65,154 ) (31,925 ) Other income (expense), net: Grant income 204 138 597 2,145 Interest income (expense), net 5 (9 ) 11 (53 ) Remeasurement of derivative liabilities and convertible notes — (4,720 ) (281 ) (7,515 ) Total other income (expense), net 209 (4,591 ) 327 (5,423 ) Net loss $ (7,815 ) $ (17,187 ) $ (64,827 ) $ (37,348 ) Net loss per share of common stock, basic and diluted $ (0.20 ) $ (6.70 ) $ (1.86 ) $ (15.58 ) Weighted-average number of shares used in net loss per share of 39,029,856 2,565,252 34,768,542 2,396,798
Reconciliation of GAAP to Non-GAAP Financial Measures The following table represents the reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures: (In thousands) (Unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2021 2020 2021 2020 Reconciliation of GAAP to non-GAAP Gross Profit (Loss): GAAP Gross Profit (Loss) $ 12,625 $ (1,672 ) $ 10,224 $ (1,672 ) Stock-based compensation expense 385 17 736 17 Depreciation and amortization 1,082 87 2,259 87 Impairment of long-lived assets (183 ) — 1,439 — Inventory obsolescence charge 5,223 — 6,507 — Preapproval inventories — (60 ) (1,089 ) (60 ) Non-GAAP Gross profit (loss) $ 19,132 $ (1,628 ) $ 20,076 $ (1,628 ) Three Months Ended December 31, Twelve Months Ended December 31, 2021 2020 2021 2020 Reconciliation of GAAP to non-GAAP Gross margin GAAP Gross (negative) margin 21 % (622 %) 11 % (622 %) Stock-based compensation expense 1 % 6 % 1 % 6 % Depreciation and amortization 2 % 32 % 2 % 32 % Impairment of long-lived assets 0 % 0 % 2 % 0 % Inventory obsolescence charge 9 % 0 % 7 % 0 % Preapproval inventories 0 % (22 %) (1 %) (22 %) Non-GAAP Gross (negative) margin 31 % (605 %) 22 % (605 %) Three Months Ended December 31, Twelve Months Ended December 31, 2021 2020 2021 2020 Reconciliation of GAAP to non-GAAP Operating expenses: GAAP Operating expenses $ 20,649 $ 10,924 $ 75,378 $ 30,253 Stock-based compensation expense (1,220 ) (185 ) (7,369 ) (420 ) Depreciation and amortization (431 ) (40 ) (1,412 ) (193 ) Preapproval inventories - 893 305 893 Non-GAAP Operating expenses $ 18,998 $ 11,592 $ 66,902 $ 30,533 Three Months Ended December 31, Twelve Months Ended December 31, 2021 2020 2021 2020 Reconciliation of GAAP to non-GAAP Net loss: GAAP Net loss $ (7,815 ) $ (17,187 ) $ (64,827 ) $ (37,348 ) Stock-based compensation expense 1,605 202 8,105 437 Depreciation and amortization 1,513 127 3,671 280 Non-cash interest and other expense 5 4,729 270 7,568 Impairment of long-lived assets (183 ) — 1,439 — Inventory obsolescence charge 5,223 — 6,507 — Preapproval inventories — (953 ) (1,394 ) (953 ) Non-GAAP Net Income (loss) $ 348 $ (13,082 ) $ (46,229 ) $ (30,016 )
